186 related articles for article (PubMed ID: 31126075)
1. Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis.
Chen PH; Ho CL; Lin C; Wu YY; Huang TC; Tu YK; Lee CH
J Clin Med; 2019 May; 8(5):. PubMed ID: 31126075
[TBL] [Abstract][Full Text] [Related]
2. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
[TBL] [Abstract][Full Text] [Related]
3. A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.
Lee CH; Chen PH; Lin C; Wang CY; Ho CL
PLoS One; 2020; 15(1):e0226879. PubMed ID: 31995577
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves.
Alrawashdh N; Persky DO; McBride A; Sweasy J; Erstad B; Abraham I
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e820-e831. PubMed ID: 34274291
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
7. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
8. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
10. Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia.
Yang S; Li N; Zhu R; Feng Y; Zhuo J; Gale RP; Huang X
Ann Hematol; 2023 Aug; 102(8):2181-2188. PubMed ID: 37393401
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review.
Sardar M; Malik SU; Khan A; Idrees M; Ahmad Q; Sohail C; Naseer R; Amin S; McBride A; Abuzar M; Safdar A; Chakraborty R; Lee P; Sharon D; Anwer F
J Hematol; 2019 Mar; 8(1):1-10. PubMed ID: 32300434
[TBL] [Abstract][Full Text] [Related]
12. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Barrientos JC; O'Brien S; Brown JR; Kay NE; Reddy NM; Coutre S; Tam C; Mulligan S; Jaeger U; Devereux S; Pocock C; Robak T; Schuster SJ; Schuh A; Gill D; Bloor A; Dearden C; Moreno C; Cull G; Hamblin M; Jones JA; Eckert K; Solman IG; Suzuki S; Hsu E; James DF; Byrd JC; Hillmen P
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):803-813.e7. PubMed ID: 30249389
[TBL] [Abstract][Full Text] [Related]
13. Current Treatment of Chronic Lymphocytic Leukemia.
Jamroziak K; Puła B; Walewski J
Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib Plus Venetoclax for First-Line Chronic Lymphocytic Leukemia Treatment.
Wierda WG
NEJM Evid; 2022 Jul; 1(7):EVIDe2200093. PubMed ID: 38319264
[TBL] [Abstract][Full Text] [Related]
16. What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?
Cheson BD
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):723-727. PubMed ID: 28780145
[TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
18. Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
Sheng Z; Song S; Yu M; Zhu H; Gao A; Gao W; Ran X; Huo D
Leuk Lymphoma; 2020 Dec; 61(14):3432-3439. PubMed ID: 32862749
[TBL] [Abstract][Full Text] [Related]
19. Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?
Cuneo A; Foà R
Mediterr J Hematol Infect Dis; 2019; 11(1):e2019024. PubMed ID: 30858962
[TBL] [Abstract][Full Text] [Related]
20. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
Deng R; Gibiansky L; Lu T; Agarwal P; Ding H; Li X; Kshirsagar S; Lu D; Li C; Girish S; Wang J; Boyer M; Humphrey K; Freise KJ; Salem AH; Seymour JF; Kater AP; Miles D
Clin Pharmacokinet; 2019 Dec; 58(12):1621-1634. PubMed ID: 31209657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]